Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Journey Medical CorporationNASDAQ: DERM
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $8.62M rose 18.3% year over year, ahead of the +7.6% change in trailing-twelve-month gross profit. Sequentially, it fell 10.0% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Gross profit amounted to 59.3% of revenue in FY2025, down 3.5 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of +7.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 36.68M USD
- Year-over-year change
- +4.0%
- 4-year CAGR
- +4.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.68M | +4.0% |
| FY2024 | 2024-12-31 | 35.26M | -32.9% |
| FY2023 | 2023-12-31 | 52.52M | +22.4% |
| FY2022 | 2022-12-31 | 42.89M | +38.1% |
| FY2021 | 2021-12-31 | 31.05M | — |
Gross Profit vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.6% is the 6th highest of 10, against a peer median of +54.0%.
- Gross profit amounts to 60.4% of revenue for DERM, versus a peer median of 48.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$97.71M CAD | +54.0% | — | 35.6% | |
| LTM Mar 2026 | $47.04M USD | +68.6% | +204.4% | 92.2% | |
| LTM Mar 2026 | $46.35M USD | -32.6% | -31.3% | 41.0% | |
| LTM Mar 2026 | $39.07M USD | +7.6% | -5.1% | 60.4% | |
| LTM Mar 2026 | $32.49M USD | +1115.8% | +118.1% | 99.3% | |
| LTM Mar 2026 | $9.03M USD | +6284.9% | +157.3% | 94.2% | |
| LTM Mar 2026 | €7.89M EUR | +175.8% | +48.4% | 48.3% | |
| LTM Mar 2026 | $2.84M USD | +2.7% | -37.2% | 19.6% | |
| FY2025 | €1.51M EUR | -83.6% | -55.4% | 33.7% | |
| LTM Mar 2026 | -$11.02M USD | -132.3% | -70.5% | 621.0% | |
| Peer median (excluding DERM) | — | +54.0% | +8.6% | 48.3% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.